DIDAK INJECTION financials
A multi-period view of the public annual-account figures reported for DIDAK INJECTION, with comparable measures and links to available source documents.
Company overviewRegistry number
0428125831
Fiscal coverage
2024–2025
Public sources
cbso_bulk
Data updated
Jul 30, 2026
Financial evidence
Latest movements for DIDAK INJECTION
2025 versus 2024
- Operating line
- €43,493,346
- EBITDA
- €6,155,957
- Total assets
- €25,250,499
- Equity
- €14,388,858
+11%
+4.1%
+1.1%
+8.3%
EBITDA margin +14.2% · Equity ratio +57%
Multi-year filings
Source: NBB/CBSOFiled annual accounts by fiscal year
Public regulator-filed figures across 2 years.
Fiscal year | Revenue | EBITDA | Total assets | Equity | Filing |
|---|---|---|---|---|---|
| 202531 Dec 2025 | €43,493,346 | €6,155,957 | €25,250,499 | €14,388,858 | - |
| 202431 Dec 2024 | €39,178,519 | €5,916,202 | €24,970,438 | €13,284,773 | - |
Figures reproduce public filings and may use country-specific accounting definitions. They are not audited by Upswitch.